Skip to main content

Table 2 Comparison of AECOPD inpatients with and without IPA in the training set

From: A risk-predictive model for invasive pulmonary aspergillosis in patients with acute exacerbation of chronic obstructive pulmonary disease

Characteristic No. (%)* P
IPA (n = 59) Non-IPA (n = 557)
Age, years    
 Median (range) 72 (67, 82) 76 (68, 84) 0.08
Male gender 55 (93.2) 470 (84.4) 0.69
Smoking index > 400 16 (27.1) 97 (17.4) 0.07
Comorbidities    
 Previous tuberculosis 6 (10.2) 31 (5.6) 0.15
 Lung cancer 4 (6.8) 21 (3.8) 0.29
 Bronchiectasis 1 (1.7) 7 (1.3) 0.78
 Asthma 1 (1.7) 17 (3.1) 0.56
 Lobectomy surgery 1 (1.7) 12 (2.2) 0.82
 Other solid tumor 0 (0) 23 (4.1) 0.11
 Hypertension 21 (35.6) 276 (49.6) 0.04
 Diabetes mellitus 7 (11.9) 87 (15.6) 0.44
 Congestive heart failure 13 (22) 106 (19) 0.57
 Chronic and acute kidney disease 4 (6.8) 40 (7.2) 0.96
 Advanced liver disease 2 (3.4) 6 (1.1) 0.14
 Connective tissue disease 0 (0) 13 (2.3) 0.24
Laboratory results    
 Serum albumin < 30 g/L 29 (49.2) 122 (21.9)  < 0.01
 GOLD III–IV 56 (94.9) 353 (63.4)  < 0.01
 Respiratory failure 13 (22) 116 (20.8) 0.83
Co-infection    
 Lung bacterial infection 10 (16.9) 90 (16.2) 0.88
 Pulmonary tuberculosis 0 (0) 12 (2.2) 0.25
Previous treatment    
 Inhale corticosteroids 11 (18.6) 113 (20.3) 0.76
 Oral or intravenous corticosteroids 18 (30.5) 41 (7.4)  < 0.01
 Cytotoxic drug utility 0 (0) 2 (0.4) 0.64
 Broad-spectrum antibiotic > 10 days 17 (28.8) 28 (5)  < 0.01
 Invasive ventilator utility 9 (15.3) 40 (7.2) 0.03
 ICU admission 1 month prior 10 (16.9) 44 (7.9) 0.02
Hospital acute exacerbation ≥ 2/year 20 (33.9) 91 (16.3)  < 0.01
  1. IPA invasive pulmonary aspergillosis, GOLD global initiative for chronic obstructive lung disease, ICU intensive care unit
  2. *Values are presented as numbers and percentages, unless otherwise indicated